These results might be due to the different responses of patients without diabetes to liraglutide treatment by different mechanisms such as attenuation of gastric lipid production or delayed gastric emptying rather than insulin resistance reduction in T2D patients (Hermansen et al., 2013; Madsbad, 2019). This evidence concerns the gene INS and type 2 diabetes mellitus.